Koglok Tablet contains Alpha Ketoanalogue (NA), a vital adjunctive therapy used primarily in the management of chronic kidney disease (CKD). Alpha Ketoanalogue serves as a nitrogen-free analogue of essential amino acids, designed to reduce the accumulation of nitrogenous waste products in patients with impaired renal function. By providing these ketoanalogues, Koglok Tablet aids in minimizing the intake of dietary protein while preventing malnutrition and maintaining a positive nitrogen balance. This therapeutic approach helps to slow the progression of renal failure and delay the need for dialysis. Koglok is typically administered alongside a low-protein diet under medical supervision. The tablet is well-tolerated, with minimal adverse effects reported when used as directed. It is contraindicated in patients with hypersensitivity to any component of the formulation and should be used cautiously in those with severe hepatic impairment. Regular monitoring of renal function, nutritional status, and serum electrolytes is recommended during therapy to optimize outcomes. Koglok Tablet is an essential component in the comprehensive management of CKD, contributing to improved patient quality of life and clinical prognosis through its unique mechanism of action in nitrogen metabolism.